Ehave is developing software-based solutions for the digital management, assessment, and remediation of the most common mental health disorders faced by children and adolescents, with an initial focus on attention deficit hyperactivity disorder (“ADHD”).
Stock Performance
Ehave News 13 articles
- Ehave Provides Progress Update on its HPPD Study with University of Melbourne
- FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder
- Ehave Shareholder from CEO Ben Kaplan and Corporate Update
- Ehave Expands Its KetaDASH Brand And Begins Producing Revenue With The Purchase Of California Based Rejuv IV
- Ehave, Inc. Engages Legal Counsel on Launch of KetaDASH in the U.S.
- Ehave to Launch Ketamine Trials Using Brain Mapping Technology
- Ehave, Inc. Utilizes Artificial Intelligence and Machine Learning for Big Data Management in Mental Healthcare
- Ehave, Inc. Files to List on the Canadian Stock Exchange and Applies to Upgrade to OTCQB Exchange
- Ehave, Inc. Announces KetaDASH for Ketamine Home Delivery and Purchase of Curedash Assets
- Ehave, Inc. Launches Premier Psychedelic Retreat Centers Partnership and MyLifeID Card Giveaway
- Ehave Announces Plans to Enter the $30 Billion Patient Medical Records Industry and the $6.38 Billion Telepsychiatry Industry Through a Licensing Agreement with Active Doctors
- Ehave Signs Licensing Agreement to Enhance its Telemedicine Platform
- Ehave Announces Plans to Accelerate the Monetization of its Proprietary Digital Health Platform